Parkinson’s disease (PD) is the second commonest neurodegenerative disorder in the older adult and is characterized by progressive disabling motor symptoms of bradykinesia, tremor, rigidity, postural instability and also non motor symptoms that affect quality of life. The pharmacotherapy of PD consists of oral, transdermal, and subcutaneous medications, as well as invasive advanced therapies at later stages of the disease. PD medications are often started as monotherapy but with the progression of the illness often there is a need to add more medications and frequently comprises of a challenging polypharmacotherapy. Adverse effects of pharmacotherapy often add to the problems of adequate treatment. Patients and physicians have to prioritize treatment goals on the most disabling symptoms and the safest and most effective treatments. Almost every year newer medications and modes of delivery continue to be researched and added to the therapeutic armamentarium. This review article outlines existing and emerging pharmacotherapies for motor symptoms in PD.
NuttJGFellmanJH. Pharmacokinetics of levodopa. Clin Neuropharmacol. 1984;7(1):35–49.
5.
YahrMDDuvoisinRCMendozaMRSchearMJBarrettRE. Modification of L-DOPA therapy of Parkinsonism by alphamethyldopa hydrazine (MK-486). Trans Am Neurol Assoc. 1971;96:55–58.
6.
PoeweWHLeesAJSternGM. Treatment of motor fluctuations in Parkinson’s disease with an oral sustained-release preparation of L-dopa: clinical and pharmacokinetic observations. Clin Neuropharmacol. 1986;9(5):430–439.
7.
AhlskogJEMuenterMDMcManisPGBellGNBaileyPA. Controlled-release Sinemet (CR-4): a double-blind crossover study in patients with fluctuating Parkinson’s disease. Mayo Clin Proc. 1988;63(9):876–886.
8.
HsuAYaoHMGuptaSModiNB. Comparison of the pharmacokinetics of an oral extended-release capsule formulation of carbidopa-levodopa (IPX066) with immediate-release carbidopa-levodopa (Sinemet(®)), sustained-release carbidopa-levodopa (Sinemet(®) CR), and carbidopa-levodopa-entacapone (Stalevo(®)). J Clin Pharmacol. 2015;55(9):995–1003. doi:10.1002/jcph.514
9.
AquinoCCFoxSH. Clinical spectrum of levodopa-induced complications. Mov Disord. 2015;30(1):80–90.
10.
WrightBAWatersCH. Continuous dopaminergic delivery to minimize motor complications in Parkinson’s disease. Expert Rev Neurother. 2013;13(6):719–729.
11.
ChaseTN. The significance of continuous dopaminergic stimulation in the treatment of Parkinson’s disease. Drugs. 1998;55(suppl 1):1–9.
12.
DhallRKreitzmanDL. Advances in levodopa therapy for Parkinson disease: review of RYTARY (carbidopa and levodopa) clinical efficacy and safety. Neurology. 2016;86(14 Suppl 1):S13–24. doi:10.1212/WNL.0000000000002510
13.
PilleriMAntoniniA. Novel levodopa formulations in the treatment of Parkinson’s disease. Expert Rev Neurother. 2014;14(2):143–149.
14.
MargoleskyJSingerC. Extended-release oral capsule of carbidopa-levodopa in Parkinson disease. Ther Adv Neurol Disord. 2017;11:1756285617737728. doi:10.1177/1756285617737728
KianiradYSimuniT. Novel approaches to optimization of levodopa therapy for Parkinson’s Disease. Curr Neurol Neurosci Rep. 2016;16(4):34. doi:10.1007/s11910-016-0635- 8
17.
PoeweWAntoniniA. Novel formulations and modes of delivery of Levodopa. Mov Disord. 2015;30(1):114–120. doi:10.1002/MDS. 26078
18.
LeWittPAFriedmanHGiladiN. Accordion pill carbidopa/ levodopa for improved treatment of advanced Parkinson’s disease symptoms. Mov Disord. 2012;27(1):S408.
19.
LeWittPAGiladiNGurevichT. Accordion pill carbidopa/ levodopa (AP CD/LD) to treat advanced Parkinson’s disease (PD). Mov Disord. 2014;29(1):S248.
20.
OlanowCWObesoJAStocchiF. Continuous dopamine receptor stimulation in the treatment of Parkinson’s disease: scientific rationale and clinical implications. Lancet Neurology. 2006;5(8):677–687.
21.
WirdefeldtKOdinPNyholmD. Levodopa-carbidopa intestinal gel in patients with Parkinson’s disease: a systematic review. CNS Drugs. 2016;30(5):381–404. doi:10.1007/s40263-016-0336-5
22.
PahwaRLyonsKE. Outpatient titration of carbidopa/levodopa enteral suspension (Duopa). Int J Neurosci. 2017;127(5):459–465. doi:10.1080/00207454.2016.1193862
23.
BlaiseASBailleGCarrièreN., et al.Safety and effectiveness of levodopa-carbidopa intestinal gel for advanced Parkinson’s disease: a large single-center study. Rev Neurol (Paris). 2020;176(4):268–276. doi:10.1016/j.neurol.2019.07.024 Epub 2019 Oct 23.
24.
BredenbergSNyholmDAquiloniusSMNyströmC. An automatic dose dispenser for micro tablets—a new concept for an individual dosage of drugs in tablet form. Int J Pharm. 2003;261(1-2):137–146. doi:10.1016/S0378-5173(03)00294 -1
25.
AquiloniusSMNyholmD. Development of new levodopa treatment strategies in Parkinson’s disease-from bedside to bench to bedside. Ups J Med Sci. 2017;122(2):71–77. doi:10.1080/03009734.2017.1285374
26.
NyholmDEhrneboMLewanderT, et al.Frequent administration of levodopa/carbidopa micro tablets vs levodopa/carbidopa/entacapone in healthy volunteers. Acta Neurol Scand. 2013;127(2):124–132. doi:10.1111/j.1600-0404.2012.01700.x
27.
OndoWGShinawiLMooreS. Comparison of orally dissolving carbidopa/levodopa (Parcopa) to conventional oral carbidopa/levodopa: A single-dose, double-blind, double-dummy, placebo-controlled, crossover trial. Mov Disord. 2010;25(16):2724–2727. doi:10.1002/mds.23158
28.
TambascoNRomoliMCalabresiP. Levodopa in Parkinson’s disease: current status and future developments. Curr Neuropharmacol. 2018;16(8):1239–1252. doi:10.2174/1570159X15666170510143821
29.
LippMMBatyckyRMooreJLeinonenMFreedMI. Preclinical and clinical assessment of inhaled Levodopa for OFF episodes in Parkinson’s disease. Sci Transl Med. 2016;8(360):360ra136. doi:10.1126/scitranslmed.aad8858
30.
StocchiFVaccaLStirpePTortiM. Pharmacokinetic drug evaluation of CVT-301 for the treatment of Parkinson’s disease. Expert Opin Drug Metab Toxicol. 2018;14(12):1189–1195. Luinstra M, Grasmeijer F, Hagedoorn P, Moes JR, Frijlink HW, de Boer AH. A levodopa dry powder inhaler for the treatment of Parkinson’s disease patients in off periods. 2015.
31.
LeWittPAHauserRAGrossetDG, et al.A randomized trial of inhaled Levodopa (CVT-301) for motor fluctuations in Parkinson’s disease. Mov Disord. 2016;31(9):1356–1365. doi:10.1002/mds.26611
32.
LeWittPAHauserRAPahwaR, et al.Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson’s disease: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Neurol. 2019;18(2):145–154. doi:10.1016/S1474-4422(18)30405-8
33.
FacherisMCriswellSPavasiaN, et al.Safety and tolerability during a 4-week continuous subcutaneous infusion of ABBV-951, a new drug formulation for the treatment of Parkinson’s Disease: final results of a phase 1b study [Abstract 1384]. Neurology. 2020;94(15 Suppl).
34.
Warren OlanowCEspayAJStocchiF, et al.Continuous subcutaneous levodopa delivery for Parkinson’s disease: a randomized study. J Parkinsons Dis. 2021;11(1):177–186. doi:10.3233/JPD-202285
35.
WoodLD. Clinical review and treatment of select adverse effects of dopamine receptor agonists in Parkinson’s disease. Drugs Aging. 2010;27(4):295–310.
36.
AhlskogJEMuenterMD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord. 2001;16(3):448–458.
37.
SchragABen-ShlomoYQuinnN. How common are complications of Parkinson’s disease?J Neurol. 2002;249(4):419–423.
38.
FahnS. Parkinson’s disease, the effect of Levodopa, and the ELLDOPA trial earlier vs later l-DOPA. Arch Neurol. 1999;56(5):529–535.
39.
Kadastik-EermeLTabaNAsserTTabaP. Factors associated with motor complications in Parkinson’s disease. Brain Behav. 2017;7(10):e00837.
40.
YasuiKNakasoKKowaHTakeshimaTNakashimaK. Levodopa-induced hyperhomocysteinemia in Parkinson’s disease. Acta Neurol Scand. 2003;108(1):66–67.
41.
SzadejkoKDziewiatowskiKSzabatK, et al.Polyneuropathy in levodopa-treated Parkinson’s patients. J Neurol Sci. 2016;371:36–41.
42.
VelseboerDCde HaanRJWielingWGoldsteinDSde BieRMA. Prevalence of orthostatic hypotension in Parkinson’s 526 M. Klietz et al. disease: a systematic review and meta-analysis. Parkinsonism Relat Disord. 2011;17(10):724–729.
43.
Alessandra Fanciulli, Nicole Campese, Georg Goebel et al. Association of transient orthostatic hypotension with falls and syncope in patients with Parkinson disease. Neurology. 2020;95(21):e2854–e2865. doi:10.1212/WNL.0000000000010749
44.
PierceyMF. Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson’s disease. Clin Neuropharmacol.1998;21(3):141–151.
45.
ChenJJSwopeDMDashtipourKLyonsKE. Transdermal rotigotine: a clinically innovative dopamine-receptor agonist for the management of Parkinson’s disease. Pharmacotherapy. 2009;29(12):1452–1467.
46.
TullochIF. Pharmacologic profile of ropinirole: a non ergoline dopamine agonist. Neurology. 1997;49(1 Suppl 1):S58–S62.
47.
HubbleJP. Long-term studies of dopamine agonists. Neurology. 2002;58(4 Suppl 1):S42–S50.
48.
JennerP. Pharmacology of dopamine agonists in the treatment of Parkinson’s disease. Neurology. 2002;58:(4 Suppl 1):S1–8.
49.
EdenRJCostallBDomeneyAM, et al.Preclinical pharmacology of ropinirole (SK&F 101468-A) a novel dopamine D2 agonist. Pharmacol Biochem Behav. 1991;38(1):147–154.
50.
RascolOBrooksDJBruntERKorczynADPoeweWHStocchiF. Ropinirole in the treatment of early Parkinson’s disease: a 6-month interim report of a 5-year levodopa-controlled study. 056 Study Group. Mov Disord. 1998;13(1):39–45.
51.
BrooksDJAbbottRJLeesAJ, et al.A placebo-controlled evaluation of ropinirole, a novel D2 agonist, as sole dopaminergic therapy in Parkinson’s disease. Clin Neuropharmacol. 1998;21(2):101–107.
52.
SethiKDO’BrienCFHammerstadJP, et al.Ropinirole for the treatment of early Parkinson disease: a 12-month experience. Ropinirole Study Group. Arch Neurol.1998;55(9):1211–1216.
53.
BrooksDJTorjanskiNBurnDJ. Ropinirole in the symptomatic treatment of Parkinson’s disease. J Neural Transm Suppl. 1995;45:231–238.
54.
LiebermanAOlanowCWSethiK. Ropinirole Study Group: a multicenter trail of ropinirole as adjunct treatment for Parkinson’s disease. Neurology. 1998;51(4):1057–1062.
55.
WhoneALWattsRLStoesslAJ, et al.Slower progression of Parkinson’s disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol. 2003;54(1):93–101.
56.
GoetzCGBlasucciLStebbinsGT. Switching dopamine agonists in advanced Parkinson’s disease: is rapid titration preferable to slow?Neurology. 1999;52(6):1227–1229.
57.
MierauJSchingnitzG. Biochemical and pharmacological studies on pramipexole, a potent and selective dopamine D2 receptor agonist. Eur J Pharmacol. 1992;215(2-3):161–170.
58.
BennettJPJrPierceyMF. Pramipexole – a new dopamine agonist for the treatment of Parkinson’s disease. J Neurol Sci. 1999;163(1):25–31.
59.
LiebermanARanhoskyAKortsD. Clinical evaluation of pramipexole in advanced Parkinson’s disease: results of a double-blind, placebo-controlled, parallel-group study. Neurology. 1997;49(1):162–168.
60.
PinterMMPogarellOOertelWH. Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson’s disease: a double blind, placebo controlled, randomised, multicentre study. J Neurol Neurosurg Psychiatry. 1999;66(4):436–441.
61.
WeinerWJFactorSAJankovicJ, et al.The long-term safety and efficacy of pramipexole in advanced Parkinson’s disease. Parkinsonism Relat Disord. 2001;7(2):115–120.
62.
Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. Parkinson Study Group. JAMA. 2000;284(15):1931–1938.
63.
HollowayRGShoulsonIFahnS, et al.Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol. 2004;61(7):1044–1053.
64.
EmbodenWA. Transcultural use of narcotic water lilies in ancient Egyptian and Maya drug ritual. J Ethnopharmacol. 1981;3(1):39–83.
65.
TabaPLeesASternG. Erich Harnack (1852-1915) and a short history of apomorphine. Eur Neurol. 2013;69(6):321–324.
66.
De WeillE. l’apomorphine dans certains troubles nerveux. Lyon Med. 1884;47:411–418.
67.
AuffretMDrapierSVérinM. Pharmacological insights into the use of apomorphine in Parkinson’s disease: clinical relevance. Clin Drug Investig. 2018;38(4):287–312. doi:10.1007/s40261-018-0619-3
68.
JennerPKatzenschlagerR. Apomorphine—pharmacological properties and clinical trials in Parkinson’s disease. Park Relat Disord. 2016;33(Suppl 1):S13–S21. doi:10.1016/j.parkreldis.2016.12.003
69.
CarboneFDjamshidianASeppiKPoeweW. Apomorphine for Parkinson’s disease: efficacy and safety of current and new formulations. CNS Drugs. 2019;33(9):905–918.
70.
MerelloMPikielnyRCammarotaALeiguardaR. Comparison of subcutaneous apomorphine versus dispersible madopar latency and effect duration in Parkinson's disease patients. Clin Neuropharmacol. 2006;20(2):165–167.
71.
GancherSTNuttJGWoodwardWR. Absorption of apomorphine by various routes in parkinsonism. Mov Disord. 1991;6(3):212–216.
72.
HauserRAIsaacsonSClinchT; Tigan/Apokyn Study Investigators. Randomized, placebo-controlled trial of trimethobenzamide to control nausea and vomiting during initiation and continued treatment with subcutaneous apomorphine injection. Parkinsonism Relat Disord. 2014;20(11):1171–1176. doi:10.1016/j.parkreldis.2014.08.010
73.
HauserRAOlanowCWDzyngelB, et al.Sublingual apomorphine (APL-130277) for the acute conversion of OFF to ON in Parkinson’s disease. Mov Disord. 2016;31(9):1366–1372.
74.
OlanowCWFactorSAEspayAJ, et al.Apomorphine sublingual film for off episodes in Parkinson’s disease: a randomised, double-blind, placebo-controlled phase 3 study. Lancet Neurol. 2020;19(2):135–144. doi:10.1016/S1474-4422(19)30396-5
75.
TrenkwalderCChaudhuriKRGarcía RuizPJ, et al.Expert Consensus Group report on the use of apomorphine in the treatment of Parkinson’s disease—Clinical practice recommendations. Parkinsonism Relat Disord. 2015;21(9):1023–1030. doi:10.1016/j.parkreldis.2015.06.012
76.
KatzenschlagerRPoeweWRascolO, et al.Apomorphine subcutaneous infusion in patients with Parkinson’s disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet Neurology. 2018:17(9):749–759. doi:10.1016/S1474-4422(18)30239-4
77.
JennerP. A novel dopamine agonist for the transdermal treatment of Parkinson’s disease. Neurology. 2005;65(Suppl 1):S3–5.
78.
PfeifferRF. A promising new technology for Parkinson’s disease. Neurology. 2005;65(2 Suppl 1):S6–10.
79.
BraunMCawelloWPooleKHorstmannR. Steady-state pharmacokinetics of rotigotine in patients with early-stage Parkinson’s disease [abstract]. In: 9th Congress of the European Federation of Neurological Societies, September 17-20, 2005, Athens. 2005b.
80.
Bertaina-AngladeVLa RochelleCDSchellerDK. Antidepressant properties of rotigotine in experimental models of depression. Eur J Pharmacol. 2006;548(1-3):106–114.
81.
Parkinson Study Group. A controlled trial of rotigotine monotherapy in early Parkinson’s disease. Arch Neurol. 2003;60(12):1721–1728.
82.
Rosa-GriloMQamarMATaddeiRN, et al.Rotigotine transdermal patch and sleep in Parkinson’s disease: where are we now?NPJ Parkinsons Dis. 2017;3:28.
83.
LeWittPANausiedaPAChangF, et al.Rotigotine transdermal system as adjunctive therapy to levodopa in patients with advanced-stage Parkinson’s disease. Results of a randomized, double blind, placebo controlled, multicenter, multinational trial [abstract]. In: 9th Congress of the European Federation of Neurological Societies, September 17-20, 2005, Athens. 2005. p. SC115.
84.
NomotoMIwakiHKondoHSakuraiM. Efficacy and safety of rotigotine in elderly patients with Parkinson’s disease in comparison with the non-elderly: a post hoc analysis of randomized, double-blind, placebo-controlled trials. J Neurol. 2018;265(2):253–265.
85.
KulisevskyJPagonabarragaJ. Tolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of Parkinson’s disease: meta-analysis of randomized controlled trials. Drug Saf. 2010;33(2):147–161.
86.
MiyasakiJM. Evidence-based initiation of dopaminergic therapy in Parkinson’s disease. J Neurol. 2010;257(Suppl. 2):S309–313.
87.
AntoniniAChaudhuriKRBoroojerdiB, et al.Impulse control disorder related behaviours during long-term rotigotine treatment: a post hoc analysis. Eur J Neurol. 2016;23(10):1556–1565.
88.
PausSBrechtHMKosterJSeegerGKlockgetherTWullnerU. Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson’s disease. Mov Disord. 2003;18(6):659–667.
89.
EtminanMGillSSamiiA. Comparison of the risk of adverse events with pramipexole and ropinirole in patients with Parkinson’s disease: a meta-analysis. Drug Saf. 2003;26:439–444.
KaminiotiANNikitasGTTerlisAKManolisAGThomaidesTPanousopoulouAN. Ventricular bigeminy after subcutaneous administration of apomorphine in a patient with refractory Parkinson’s disease: a case report. J Mov Disord. 2013;6(1):9–12.
92.
MullerT. Catechol-O-methyltransferase inhibitors in Parkinson’s disease. Drugs. 2015;75(2):157–174.
93.
KuoppamakiMLeinonenMPoeweW. Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson’s disease patients with wearing-of. J Neural Transm (Vienna). 2015;122(12):1709–1714.
94.
NapolitanoADel DottoPPetrozziL, et al.Pharmacokinetics and pharmacodynamics of l-Dopa after acute and 6-week tolcapone administration in patients with Parkinson’s disease. Clin Neuropharmacol. 1999;22(1):24–29.
95.
RochaJ-FAlmeidaLFalcaoA, et al.Opicapone: a short lived and very long acting novel catechol-O-methyltransferase inhibitor following multiple dose administration in healthy subjects. Br J Clin Pharmacol. 2013;76(5):763–775.
96.
FerreiraJJLeesARochaJ-F, et al.Opicapone as an adjunct to levodopa in patients with Parkinson’s disease and end-of-dose motor fuctuations: a randomised, double-blind, controlled trial. Lancet Neurol. 2016;15(2):154–165.
97.
AntoniniAAbbruzzeseGBaroneP, et al.COMT inhibition with tolcapone in the treatment algorithm of patients with Parkinson’s disease (PD): relevance for motor and non-motor features. Neuropsychiatr Dis Treat. 2008;4(1):1–9.
98.
OlanowCWWatkinsPB. Tolcapone: an efcacy and safety review (2007). Clin Neuropharmacol. 2007;30(5):287–294.
99.
LeesAJRatziuVTolosaEOertelWH. Safety and tolerability of adjunctive tolcapone treatment in patients with early Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2007;78(9):944–948.
100.
UngerMMReeseJPOertelWHEggertKM. Real-life evaluations of compliance with mandatory drug safety monitoring exemplifed with tolcapone in Parkinson’s disease. Eur Neurol. 2008;60(3):122–126.
101.
RodriguesFBFerreiraJJ. Opicapone for the treatment of Parkinson’s disease. Expert Opin Pharmacother. 2017;18(4):445–453.
102.
KalgutkarASDalvieDKCastagnoliNJTaylorTJ. Interactions of nitrogen-containing xenobiotics with monoamine oxidase (MAO) isozymes A and B: SAR studies on MAO substrates and inhibitors. Chem Res Toxicol. 2001;14(9):1139–1162.
103.
FernandezHHChenJJ. Monoamine oxidase-B inhibition in the treatment of Parkinson’s disease. Pharmacotherapy. 2007;27(12 Pt 2):174S–85S.
104.
DashtipourKChenJJKaniCBahjriKGhamsaryM. Clinical outcomes in patients with Parkinson’s disease treated with a monoamine oxidase type-B inhibitor: a cross-sectional, cohort study. Pharmacotherapy. 2015;35(7):681–686.
105.
DezsiLVecseiL. Monoamine oxidase B inhibitors in Parkinson’s disease. CNS Neurol Disord Drug Targets. 2017;16(4):425–439.
106.
HauserRASilverDChoudhryAEyalEIsaacsonS. Randomized, controlled trial of rasagiline as an add-on to dopamine agonists in Parkinson’s disease. Mov Disord. 2014;29(8):1028–1034.
107.
RombergRWNeedlemanSBSnyderJJGreedanA. Methamphetamine and amphetamine derived from the metabolism of selegiline. J Forensic Sci. 1995;40(6):1100–1102.
108.
StocchiFTortiM. Adjuvant therapies for Parkinson’s disease: critical evaluation of safnamide. Drug Des Dev Ther. 2016;10:609–618.
109.
Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol. 2002;59(12):1937–1943.
110.
ElmerLSchwidSEberlyS, et al.Rasagiline-associated motor improvement in PD occurs without worsening of cognitive and behavioral symptoms. J Neurol Sci. 2006;248(1-2):78–83.
111.
RichardIHKurlanRTannerC, et al.Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson’s disease in Parkinson Study Group. Neurology. 1997;48(4):1070–1077.
112.
PanissetMChenJJRhyeeSHConnerJMathenaJ; STACCATO study investigators[Corporate Author]. Serotonin toxicity association with concomitant antidepressants and rasagiline treatment: retrospective study (STACCATO). Pharmacotherapy. 2014;34(12):1250–1258. doi:10.1002/phar.1500
113.
AboukarrAGiudiceM. Interaction between monoamine oxidase B inhibitors and selective serotonin reuptake inhibitors. Can J Hosp Pharm. 2018;71(3):196–207.
114.
TaylorJJWilsonJWEstesLL. Linezolid and serotonergic drug interactions: a retrospective survey. Clin Infect Dis. 2006;43(2):180–187.
115.
NicholsonKGWiselkaMJ. Amantadine for influenza A. BMJ. 1991;302(6774):425–426.
116.
HubsherGHaiderMOkunMS. Amantadine: the journey from fighting flu to treating Parkinson disease. Neurology. 2012;78(14):1096–1099.
117.
SchwabRSEnglandACJrPoskanzerDCYoungRR. Amantadine in the treatment of Parkinson’s disease. JAMA. 1969;208(7):1168–1170.
118.
MizoguchiKYokooHYoshidaMTanakaTTanakaM. Amantadine increases the extracellular dopamine levels in the striatum by re-uptake inhibition and by N-methyl-d-aspartate antagonism. Brain Res. 1994;662(1-2):255–258.
119.
PahwaRTannerCMHauserRA, et al.Amantadine extended release for levodopa-induced dyskinesia in Parkinson’s disease (EASED Study). Mov Disord. 2015;30(6):788–795.
120.
OertelWEggertKPahwaR, et al.Randomized, placebo-controlled trial of ADS5102 (amantadine) extended-release capsules for levodopa induced dyskinesia in Parkinson’s disease (EASE LID 3). Mov Disord. 2017;32(12):1701–1709.
121.
PahwaRTannerCMHauserRA, et al.ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson disease (EASE LID Study): a randomized clinical trial. JAMA Neurol. 2017;74(8):941–949.
122.
HauserRAPahwaRWarginWA, et al.Pharmacokinetics of ADS-5102 (Amantadine) extended release capsules administered once daily at bedtime for the treatment of Dyskinesia.”Clinical Pharmacokinet. 2019;58(1):77–88. doi:10.1007/s40262-018-0663-4
123.
ElkurdMTBahrooLBPahwaR. The role of extended-release amantadine for the treatment of dyskinesia in Parkinson’s disease patients. Neurodegener Dis Manag. 2018;8(2):73–80. doi:10.2217/nmt-2018-0001
124.
Müller-RebsteinSTrenkwalderCEbentheuerJOertelWHCulmseeCHöglingerGU. Drug safety analysis in a real-life cohort of Parkinson’s disease patients with polypharmacy. CNS Drugs. 2018;31(12):1093–1102.
125.
RosinDHettingerBLeeALindenJ. Anatomy of adenosine A2A receptors in brain. Neurology. 2003;61(11 Suppl 6):12–18.
126.
FinkJSWeaverDRRivkeesSA, et al.Molecular cloning of rat A2 adenosine receptor: selective co-expression with D2 dopamine receptors in rat striatum. Mol Brain Res. 1992;14(3):186–190.
127.
FerréSDíaz-RíosMSalamoneJDPredigerRD. New developments on the adenosine mechanisms of the central effects of caffeine and their implications for neuropsychiatric disorders. J Caffeine Adenosine Res. 2018;8(4):121–131.
128.
SakoWMurakamiNMotohamaK, et al.The effect of istradefylline for Parkinson’s disease: a meta-analysis. Sci Rep. 2017;7(1):18018. doi:10.1038/s41598-017-18339 -1
129.
TortiMVaccaLStocchiF. Istradefylline for the treatment of Parkinson’s disease: is it a promising strategy?Expert Opin Pharmacother. 2018;19(16):1821–1828. doi:10.1080/14656566.2018.1524876
130.
ConnollyBSLangAE. Pharmacological treatment of Parkinson disease: a review. JAMA. 2014;311(16):1670–1683. doi:10.1001/jama.2014.3654
131.
BrocksDR. Anticholinergic drugs used in Parkinson’s disease: an overlooked class of drugs from a pharmacokinetic perspective. J Pharm Pharm Sci. 1999;2(2):39–46.
132.
De GermaySMontastrucJLRousseauV, et al.Atropinic (Anticholinergic) Burden in Parkinson’s Disease. Mov Disord. 2016;31(5):632–636. doi:10.1002/mds.26595
133.
KatzenschlagerRSampaioCCostaJLeesA. Anticholinergics for symptomatic management of Parkinson’s disease. Cochrane Database Syst Rev. 2003;(2):CD003735. doi:10.1002/14651858.CD003735
